title: Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation.
abstract: We have developed an ELISA for BK-(1-5) (Arg1-Pro2-Pro3-Gly4-Phe5). In rat carrageenin-induced pleurisy, in which a plasma exudation peak was observed 5 h after carrageenin, BK levels in the exudates were negligible (< 60 pg/rat). BK-(1-7) (des-Phe8-Arg9-BK) was detectable (900-400 pg/rat) over the entire course of the inflammation. However, a larger amount of BK-(1-5) was detectable in association with the increase in plasma exudation, showing a peak (8800 +/- 1200 pg/rat) 3 h after carrageenin. Bromelain (10 mg/kg, i.v.) and soy bean trypsin inhibitor (0.3 mg/rat, intra-pleural) significantly reduced BK-(1-5) levels (by 60-93%, 3, 7 and 19 h after carrageenin) and plasma exudation rates (by 61-74%, 3 and 7 h after carrageenin). Dexamethasone (0.3 mg/kg, i.p.) reduced BK-(1-5) levels (by 78%) and decreased plasma exudation (by 70%) 3 h after carrageenin. In nasal allergy patients, antigen challenge of nasal mucosa elevated BK-(1-5) levels and active kallikrein levels in nasal washes. These results verify that BK-(1-5) determined by ELISA is a good indicator for release of kinins in vivo.
authors.affiliation: Department of Pharmacology, Kitasato University School of Medicine, Kanagawa, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Majima
authors.forename: K
authors.initials: K
authors.lastname: Nishiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Iguchi
authors.forename: K
authors.initials: K
authors.lastname: Yao
authors.forename: M
authors.initials: M
authors.lastname: Ogino
authors.forename: T
authors.initials: T
authors.lastname: Ohno
authors.forename: N
authors.initials: N
authors.lastname: Sunahara
authors.forename: K
authors.initials: K
authors.lastname: Katoh
authors.forename: N
authors.initials: N
authors.lastname: Tatemichi
authors.forename: Y
authors.initials: Y
authors.lastname: Takei
authors.forename: M
authors.initials: M
authors.lastname: Katori
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000918:Antibody Specificity; D001920:Bradykinin / Q000032:analysis* / Q000096:biosynthesis; D001963:Bromelains / Q000494:pharmacology; D002138:Calibration; D002216:Captopril / Q000494:pharmacology; D002351:Carrageenan; D003907:Dexamethasone / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005122:Exudates and Transudates / Q000737:chemistry*; D006801:Humans; D008297:Male; D010998:Pleurisy / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012130:Respiratory Hypersensitivity / Q000378:metabolism / Q000473:pathology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003907:Dexamethasone; D002351:Carrageenan; D001963:Bromelains; D002216:Captopril; D001920:Bradykinin